Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal Article
Omalizumab in Allergic Diseases, a Recent Review
TL;DR: Omalizumab represents a major breakthrough of translational medicine in allergy and is primarily indicated for patients, age 6 years and over, with moderate to severe asthma (GINA step 4).
Journal ArticleDOI
Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma
TL;DR: Add-on omalizumab is well-tolerated and reduces exacerbations in children (6–<12 years) with severe persistent allergic asthma, inadequately controlled despite high-dose ICS plus a LABA.
Journal ArticleDOI
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma
Carlos Iribarren,Abdelkader Rahmaoui,Aidan A. Long,Stanley J. Szefler,Mary S. Bradley,Gillis Carrigan,Mark D. Eisner,Hubert Chen,Theodore A. Omachi,Michael E. Farkouh,Kenneth J. Rothman +10 more
TL;DR: This observational study demonstrated a higher incidence rate of CV/CBV events in the omalizumab versus the non‐omalizumAB cohort, and differences in asthma severity between cohorts likely contributed to this imbalance.
Journal ArticleDOI
The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia
Hector Ortega,Geoffrey L. Chupp,Philip G. Bardin,Arnaud Bourdin,Gilles Garcia,Benjamin Hartley,Steve Yancey,Marc Humbert +7 more
TL;DR: Mepolizumab, a humanised monoclonal antibody against IL-5, selectively inhibits eosinophilic airway inflammation and has been shown to be associated with a significant reduction in severe asthma exacerbations irrespective of the baseline IgE levels or radioallergosorbent test (RAST) status in the Dose Ranging Efficacy And safety trial.
Journal ArticleDOI
Monoclonal antibodies for the treatment of refractory asthma.
Nathan Hambly,Parameswaran Nair +1 more
TL;DR: A small proportion of patients with asthma have severe disease characterized by persistent airflow obstruction, airway hyperresponsiveness and eosinophilic airway inflammation as mentioned in this paper, and the clinical efficacy of inhibiting T helper 2-cytokine-mediated inflammatory respo
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.